Zeng R, Xu CH, Xu YN, Wang YL, Wang M. The effect of folate fortifica- tion on folic acid-based homocysteine-lowering intervention and stroke risk: a meta-analysis. Public Health Nutr. 2015;18:1514 1521. doi: 636. Zhao M, Wu G, Li Y, Wang X, Hou FF, Xu X, Qin X, Cai Y. Meta- analysis of folic acid efficacy trials in stroke prevention: in- sight into effect modifiers. Neurology. 2017;88:1830 1838. doi: 637. Zhao M, Wang X, He M, Qin X, Tang G, Huo Y, Li J, Fu J, Huang X, Cheng X, et al. Homocysteine and stroke risk: modifying effect of methylenetet- rahydrofolate reductase C677T polymorphism and folic acid intervention. 638. Etminan M, Takkouche B, Isorna FC, Samii A. Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observa- tional studies. BMJ. 2005;330:63. doi: 10.1136/bmj.38302.504063.8F 639. Bashir A, Lipton RB, Ashina S, Ashina M. Migraine and structural changes in the brain: a systematic review and meta-analysis. Neurology. 640. Serrano F, Arauz A, Uribe R, Becerra LC, Mantilla K, Zerme o F. Long-term follow-up of patients with migrainous infarction. Clin Neurol Neurosurg. 641. Hoekstra-van Dalen RA, Cillessen JP, Kappelle LJ, van Gijn J. Cerebral infarcts associated with migraine: clinical features, risk factors and follow- up. J Neurol. 1996;243:511 515. doi: 10.1007/BF00886872 642. Rothrock J, North J, Madden K, Lyden P, Fleck P, Dittrich H. Migraine and migrainous stroke: risk factors and prognosis. Neurology. 1993;43:2473 643. Kellner-Weldon F, El-Koussy M, Jung S, Jossen M, Klinger-Gratz PP, Wiest R. Cerebellar hypoperfusion in migraine attack: incidence and significance. AJNR Am J Neuroradiol. 2018;39:435 440. doi: 10.3174/ajnr.A5508 644. Sheikh HU, Pavlovic J, Loder E, Burch R. Risk of stroke associated with use of estrogen containing contraceptives in women with migraine: a sys- tematic review. Headache. 2018;58:5 21. doi: 10.1111/head.13229 645. Roberto G, Raschi E, Piccinni C, Conti V, Vignatelli L, D Alessandro R, De Ponti F, Poluzzi E. Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic re- view of observational studies. Cephalalgia. 2015;35:118 131. doi: 646. Aradi S, Kaiser E, Cucchiara B. Ischemic stroke associated with cal- citonin gene-related peptide inhibitor therapy for migraine: a case re- port. J Stroke Cerebrovasc Dis. 2019;28:104286. doi: 10.1016/j. 647. Chen ST, Hellkamp AS, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, Hacke W, Halperin JL, Hankey GJ, Mahaffey KW, et al. Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF. Eur Heart J Qual Care Clin Outcomes. 2019;5:145 152. doi: 10.1093/ehjqcco/qcy040 648. Melloni C, Dunning A, Granger CB, Thomas L, Khouri MG, Garcia DA, Hylek EM, Hanna M, Wallentin L, Gersh BJ, et al. Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and a history of cancer: insights from the ARISTOTLE Trial. Am J Med. 2017;130:1440 1448.e1. 649. Shah S, Norby FL, Datta YH, Lutsey PL, MacLehose RF, Chen LY, Alonso A. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation. Blood Adv. 2018;2:200 209. 650. Yang P, Zhu D, Xu X, Shen W, Wang C, Jiang Y, Xu G, Wu Q. Efficacy and safety of oral anticoagulants in atrial fibrillation patients with can- cer: a network meta-analysis. Heart Fail Rev. 2020;25:823 831. doi: 651. Dardiotis E, Aloizou AM, Markoula S, Siokas V, Tsarouhas K, Tzanakakis G, Libra M, Kyritsis AP, Brotis AG, Aschner M, et al. Cancer-associated stroke: pathophysiology, detection and management (review). Int J Oncol. 652. Adams HP Jr. Cancer and cerebrovascular disease. Curr Neurol Neurosci Options Neurol. 2002;4:417 425. doi: 10.1007/s11940-002-0009-1 654. Navi BB, Marshall RS, Bobrow D, Singer S, Stone JB, DeSancho MT, DeAngelis LM. Enoxaparin vs aspirin in patients with cancer and isch- emic stroke: the TEACH pilot randomized clinical trial. JAMA Neurol. 655. Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, Abboud M, Gallagher D, Kutlar A, Nichols FT, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339:5 11. doi: 656. Russell MO, Goldberg HI, Hodson A, Kim HC, Halus J, Reivich M, Schwartz E. Effect of transfusion therapy on arteriographic abnormalities and on re- currence of stroke in sickle cell disease. Blood. 1984;63:162 169. 657. Pegelow CH, Adams RJ, McKie V, Abboud M, Berman B, Miller ST, Olivieri N, Vichinsky E, Wang W, Brambilla D. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr. 658. Estcourt LJ, Fortin PM, Hopewell S, Trivella M, Wang WC. Blood trans- fusion for preventing primary and secondary stroke in people with sick- le cell disease. Cochrane Database Syst Rev. 2017;1:CD003146. doi: 659. Ware RE, Helms RW; SWiTCH Investigators. Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood. 2012;119:3925 3932. doi: 660. Ali SB, Moosang M, King L, Knight-Madden J, Reid M. Stroke recurrence in children with sickle cell disease treated with hydroxyurea following first clinical stroke. Am J Hematol. 2011;86:846 850. doi: 10.1002/ajh.22142 661. Ware RE, Davis BR, Schultz WH, Brown RC, Aygun B, Sarnaik S, Odame I, Fuh B, George A, Owen W, et al. Hydroxycarbamide versus chronic trans- fusion for maintenance of transcranial Doppler flow velocities in children with sickle cell anaemia: TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 662. Lucarelli G, Gaziev J, Isgr A, Sodani P, Paciaroni K, Alfieri C, De Angelis G, Marziali M, Simone MD, Gallucci C, et al. Allogeneic cellular gene therapy in hemoglobinopathies: evaluation of hematopoietic SCT in sickle cell anemia. Bone Marrow Transplant. 2012;47:227 230. doi: 10.1038/bmt.2011.79 663. Walters MC, Patience M, Leisenring W, Rogers ZR, Aquino VM, Buchanan GR, Roberts IA, Yeager AM, Hsu L, Adamkiewicz T, et al; Multicenter Investigation of Bone Marrow Transplantation for Sickle Cell Disease. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant. 2001;7:665 673. doi: 664. Fryer RH, Anderson RC, Chiriboga CA, Feldstein NA. Sickle cell anemia with moyamoya disease: outcomes after EDAS procedure. Pediatr Neurol. 665. Hankinson TC, Bohman LE, Heyer G, Licursi M, Ghatan S, Feldstein NA, Anderson RC. Surgical treatment of moyamoya syndrome in pa- tients with sickle cell anemia: outcome following encephaloduroarte- riosynangiosis. J Neurosurg Pediatr. 2008;1:211 216. doi: 10.3171/ 666. Pleasants S. Epidemiology: a moving target. Nature. 2014;515:S2 S3. doi: 667. Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. 668. Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, Dewi M, Temperley WH, Williams TN, Weatherall DJ, Hay SI. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet. 2013;381:142 151. doi: 669. Adams RJ, Nichols FT, McKie V, McKie K, Milner P, Gammal TE. Cerebral in- farction in sickle cell anemia: mechanism based on CT and MRI. Neurology. 670. Mack AK, Thompson AA. Primary and secondary stroke prevention in chil- dren with sickle cell disease. J Pediatr Health Care. 2017;31:145 154. 671. DeBaun MR, Gordon M, McKinstry RC, Noetzel MJ, White DA, Sarnaik SA, Meier ER, Howard TH, Majumdar S, Inusa BP, et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med. 672. Brekke LK, Diamantopoulos AP, Fevang BT, A mus J, Esper E, Gjesdal CG. Incidence of giant cell arteritis in western Norway 1972- 2012: a retrospective cohort study. Arthritis Res Ther. 2017;19:278. doi: 673. Salvarani C, Macchioni PL, Tartoni PL, Rossi F, Baricchi R, Castri C, Chiaravalloti F, Portioli I. Polymyalgia rheumatica and giant cell arteritis: a 5-year epidemiologic and clinical study in Reggio Emilia, Italy. Clin Exp Rheumatol. 1987;5:205 215. 674. Samson M, Jacquin A, Audia S, Daubail B, Devilliers H, Petrella T, Martin L, Durier J, Besancenot JF, Lorcerie B, et al. Stroke associated with giant CLINICAL STATEMENTS AND GUIDELINES Kleindorfer cell arteritis: a population-based study. J Neurol Neurosurg Psychiatry. 675. Chevalet P, Barrier JH, Pottier P, Magadur-Joly G, Pottier MA, Hamidou M, Planchon B, El Kouri D, Connan L, Dupond JL, et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year fol- lowup study of 164 patients. J Rheumatol. 2000;27:1484 1491. 676. Diamantopoulos AP, Haugeberg G, Lindland A, Myklebust G. The fast- track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a more effective strategy to improve clinical outcome in giant cell arteritis? Rheumatology (Oxford). 677. Gonz lez-Gay MA, Blanco R, Rodr guez-Valverde V, Mart nez-Taboada VM, Delgado-Rodriguez M, Figueroa M, Uriarte E. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum. 1998;41:1497 1504. doi: 678. Mazlumzadeh M, Hunder GG, Easley KA, Calamia KT, Matteson EL, Griffing WL, Younge BR, Weyand CM, Goronzy JJ. Treatment of giant cell arteri- tis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum. 679. Lopez-Diaz MJ, Llorca J, Gonzalez-Juanatey C, Pe a-Sagredo JL, Martin J, Gonzalez-Gay MA. The erythrocyte sedimentation rate is as- sociated with the development of visual complications in biopsy-proven giant cell arteritis. Semin Arthritis Rheum. 2008;38:116 123. doi: 680. Fern ndez-Fern ndez E, Monjo-Henry I, Bonilla G, Plasencia C, Miranda-Car s ME, Balsa A, De Miguel E. False positives in the ultra- sound diagnosis of giant cell arteritis: some diseases can also show the halo sign. Rheumatology (Oxford). 2020;59:2443 2447. doi: 10.1093/ 681. van der Geest KSM, Borg F, Kayani A, Paap D, Gondo P, Schmidt W, Luqmani RA, Dasgupta B. Novel ultrasonographic Halo Score for gi- ant cell arteritis: assessment of diagnostic accuracy and associa- tion with ocular ischaemia. Ann Rheum Dis. 2020;79:393 399. doi: 682. Mahr AD, Jover JA, Spiera RF, Hern ndez-Garc a C, Fern ndez-Guti rrez B, Lavalley MP, Merkel PA. Adjunctive methotrexate for treatment of gi- ant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 683. Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, et al. Trial of tocilizumab in giant-cell 684. Villiger PM, Adler S, Kuchen S, Wermelinger F, Dan D, Fiege V, B tikofer L, Seitz M, Reichenbach S. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387:1921 1927. doi: 10.1016/ 685. Onen F, Akkoc N. Epidemiology of Takayasu arteritis. Presse Med. 686. Bond KM, Nasr D, Lehman V, Lanzino G, Cloft HJ, Brinjikji W. Intracranial and extracranial neurovascular manifestations of Takayasu arteritis. AJNR Am J Neuroradiol. 2017;38:766 772. doi: 10.3174/ajnr.A5095 of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrex- ate. Arthritis Rheum. 1994;37:578 582. doi: 10.1002/art.1780370420 688. Valsakumar AK, Valappil UC, Jorapur V, Garg N, Nityanand S, Sinha N. Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu s arteritis. J Rheumatol. 2003;30:1793 1798. 689. de Souza AW, de Almeida Agustinelli R, de Cinque Almeida H, Oliveira PB, Pinheiro FA, Oliveira AC, Sato EI. Leflunomide in Takayasu arteritis: a long term observational study. Rev Bras Reumatol Engl Ed. 2016;56:371 375. 690. Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumat- ica and giant-cell arteritis. N Engl J Med. 2002;347:261 271. doi: 691. Salvarani C, Brown RD Jr, Calamia KT, Christianson TJ, Weigand SD, Miller DV, Giannini C, Meschia JF, Huston J 3rd, Hunder GG. Primary central nervous system vasculitis: analysis of 101 patients. Ann Neurol. 692. Boulouis G, de Boysson H, Zuber M, Guillevin L, Meary E, Costalat V, Pagnoux C, Naggara O; French Vasculitis Group. Primary angiitis of the central nervous system: magnetic resonance imaging spectrum of parenchymal, meningeal, and vascular lesions at baseline. Stroke. 693. Hutchinson C, Elbers J, Halliday W, Branson H, Laughlin S, Armstrong D, Hawkins C, Westmacott R, Benseler SM. Treatment of small vessel pri- mary CNS vasculitis in children: an open-label cohort study. Lancet Neurol. 694. Salvarani C, Brown RD Jr, Christianson TJ, Huston J 3rd, Giannini C, Miller DV, Hunder GG. Adult primary central nervous system vasculitis treat- ment and course: analysis of one hundred sixty-three patients. Arthritis 695. de Boysson H, Arquizan C, Touz E, Zuber M, Boulouis G, Naggara O, Guillevin L, Aouba A, Pagnoux C. Treatment and long-term outcomes of primary central nervous system vasculitis. Stroke. 2018;49:1946 1952. 696. Schuster S, Ozga AK, Stellmann JP, Deb-Chatterji M, H u ler V, Matschke J, Gerloff C, Thomalla G, Magnus T. Relapse rates and long-term outcome in primary angiitis of the central nervous system. J Neurol. 2019;266:1481 697. Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, Salvarani C, Xu W, Visvanathan S, Rahman MU; Infliximab-GCA Study Group. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med. 2007;146:621 698. Liou TH, Huang SW, Lin JW, Chang YS, Wu CW, Lin HW. Risk of stroke in patients with rheumatism: a nationwide longitudinal population-based study. Sci Rep. 2014;4:5110. doi: 10.1038/srep05110 699. Stojan G, Petri M. Atherosclerosis in systemic lupus erythemato- sus. J Cardiovasc Pharmacol. 2013;62:255 262. doi: 10.1097/ 700. Moyssakis I, Tektonidou MG, Vasilliou VA, Samarkos M, Votteas V, Moutsopoulos HM. Libman-Sacks endocarditis in systemic lupus erythematosus: prevalence, associations, and evolution. Am J Med. 701. Fasano S, Pierro L, Pantano I, Iudici M, Valentini G. Longterm hydroxy- chloroquine therapy and low-dose aspirin may have an additive effective- ness in the primary prevention of cardiovascular events in patients with systemic lupus erythematosus. J Rheumatol. 2017;44:1032 1038. doi: 702. Law ST, Ma KM, Li KK. Clinical characteristics of concurrent and se- quentially presented lupus-related protein-losing enteropathy: what are their differences? Rheumatol Int. 2013;33:85 92. doi: 10.1007/ 703. Shapiro M, Levy Y. The association between hydroxychloroquine treat- ment and cardiovascular morbidity among rheumatoid arthritis patients. 704. Sharma TS, Wasko MCM, Tang X, Vedamurthy D, Yan X, Cote J, Bili A. Hydroxychloroquine use is associated with decreased incident car- diovascular events in rheumatoid arthritis patients. J Am Heart Assoc. 705. Varona JF, Guerra JM, Bermejo F, Molina JA, Gomez de la C mara A. Causes of ischemic stroke in young adults, and evolution of the etio- logical diagnosis over the long term. Eur Neurol. 2007;57:212 218. doi: 706. Emmi G, Silvestri E, Squatrito D, Amedei A, Niccolai E, D Elios MM, Della Bella C, Grassi A, Becatti M, Fiorillo C, et al. Thrombosis in vas- culitis: from pathogenesis to treatment. Thromb J. 2015;13:15. doi: 707. Weyand CM, Goronzy JJ. Immune mechanisms in medium and large-vessel vasculitis. Nat Rev Rheumatol. 2013;9:731 740. doi: 708. Stamatis P. Giant cell arteritis versus Takayasu arteritis: an update. Mediterr J Rheumatol. 2020;31:174 182. doi: 10.31138/mjr.31.2.174 709. Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, Cassie R, Cid MC, Dasgupta B, Dejaco C, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79:19 30. doi: 10.1136/annrheumdis-2019-215672 710. Gutierrez J, Ortiz G. HIV/AIDS patients with HIV vasculopathy and VZV vasculitis: a case series. Clin Neuroradiol. 2011;21:145 151. doi: 711. Lanthier S, Armstrong D, Domi T, deVeber G. Post-varicella arteriopathy of childhood: natural history of vascular stenosis. Neurology. 2005;64:660 712. Nagel MA, Forghani B, Mahalingam R, Wellish MC, Cohrs RJ, Russman AN, Katzan I, Lin R, Gardner CJ, Gilden DH. The value of detecting CLINICAL STATEMENTS AND GUIDELINES Kleindorfer anti-VZV IgG antibody in CSF to diagnose VZV vasculopathy. Neurology. 713. Nagel MA, Cohrs RJ, Mahalingam R, Wellish MC, Forghani B, Schiller A, Safdieh JE, Kamenkovich E, Ostrow LW, Levy M, et al. The varicella zoster vi- rus vasculopathies: clinical, CSF, imaging, and virologic features. Neurology. 714. Wallace MR, Bowler WA, Murray NB, Brodine SK, Oldfield EC 3rd. Treatment of adult varicella with oral acyclovir: a randomized, pla- cebo-controlled trial. Ann Intern Med. 1992;117:358 363. doi: 715. Blocker ME, Levine WC, St Louis ME. HIV prevalence in patients with syphilis, United States. Sex Transm Dis. 2000;27:53 59. doi: 716. Callegari FM, Pinto-Neto LF, Medeiros CJ, Scopel CB, Page K, Miranda AE. Syphilis and HIV co-infection in patients who attend an AIDS outpatient clinic in Vitoria, Brazil. AIDS Behav. 2014;18(suppl 1):S104 S109. doi: 717. G nthard HF, Aberg JA, Eron JJ, Hoy JF, Telenti A, Benson CA, Burger DM, Cahn P, Gallant JE, Glesby MJ, et al; International Antiviral Society- USA Panel. Antiretroviral treatment of adult HIV infection: 2014 recom- mendations of the International Antiviral Society-USA Panel. JAMA. 718. Connor M. Human immunodeficiency virus (HIV) and stroke: tar- gets for intervention. Infect Disord Drug Targets. 2010;10:76 83. doi: 719. Connor MD. Treatment of HIV associated cerebral vasculopathy. J Neurol Neurosurg Psychiatry. 2009;80:831. doi: 10.1136/jnnp.2008.169490 720. Cutfield NJ, Steele H, Wilhelm T, Weatherall MW. Successful treatment of HIV associated cerebral vasculopathy with HAART. J Neurol Neurosurg 721. Mart nez-Longoria CA, Morales-Aguirre JJ, Villalobos-Acosta CP, G mez-Barreto D, Cashat-Cruz M. Occurrence of intracerebral aneurysm in an HIV-infected child: a case report. Pediatr Neurol. 2004;31:130 132. 722. Benjamin LA, Allain TJ, Mzinganjira H, Connor MD, Smith C, Lucas S, Joekes E, Kampondeni S, Chetcuti K, Turnbull I, et al. The role of human immunodeficiency virus-associated vasculopathy in the etiology of stroke. J Infect Dis. 2017;216:545 553. doi: 10.1093/infdis/jix340 723. Goldstein DA, Timpone J, Cupps TR. HIV-associated intracranial an- eurysmal vasculopathy in adults. J Rheumatol. 2010;37:226 233. doi: 724. Saraya T, Shimura C, Wada H, Aoshima M, Goto H. Evidence for vascular spread of varicella zoster-associated vasculopathy. Ann Intern Med. 2006; 725. WHO Secretariat. Chagas disease: control and elimination. 63th World Health Assembly. 2010. Provisional agenda item 11.14. Accessed 726. Carod-Artal FJ, Gascon J. Chagas disease and stroke. Lancet Neurol. 727. Lima-Costa MF, Matos DL, Ribeiro AL. Chagas disease predicts 10-year stroke mortality in community-dwelling elderly: the Bambui Cohort Study of Aging. Stroke. 2010;41:2477 2482. doi: 10.1161/ 728. de Sousa AS, Xavier SS, Rodriguez de Freitas GR, Hasslocher-Moreno A. Prevention strategies of cardioembolic ischemic stroke in Chagas disease. Arq Bras Cardiol. 2008;91:306 310. doi: 10.1590/s0066- 729. Connor MD, Lammie GA, Bell JE, Warlow CP, Simmonds P, Brettle RD. Cerebral infarction in adult AIDS patients: observations from the Edinburgh HIV Autopsy Cohort. Stroke. 2000;31:2117 2126. doi: 730. Morgello S, Mahboob R, Yakoushina T, Khan S, Hague K. Autopsy find- ings in a human immunodeficiency virus-infected population over 2 decades: influences of gender, ethnicity, risk factors, and time. Arch Pathol Lab Med. 2002;126:182 190. doi: 10.1043/0003- 731. Misra UK, Kalita J, Maurya PK. Stroke in tuberculous meningitis. J Neurol 732. Anderson NE, Somaratne J, Mason DF, Holland D, Thomas MG. Neurological and systemic complications of tuberculous meningitis and its treatment at Auckland City Hospital, New Zealand. J Clin Neurosci. 733. Cordato DJ, Djekic S, Taneja SR, Maley M, Beran RG, Cappelen-Smith C, Griffith NC, Hanna IY, Hodgkinson SJ, Worthington JM, et al. Prevalence of positive syphilis serology and meningovascular neurosyphilis in patients admitted with stroke and TIA from a culturally diverse population (2005- 734. Mishra AK, Arvind VH, Muliyil D, Kuriakose CK, George AA, Karuppusami R, Benton Carey RA, Mani S, Hansdak SG. Cerebrovascular in- jury in cryptococcal meningitis. Int J Stroke. 2018;13:57 65. doi: 735. Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64:1 137. 736. Fonkem E, Dayawansa S, Stroberg E, Lok E, Bricker PC, Kirmani B, Wong ET, Huang JH. Neurological presentations of intravascular lym- phoma (IVL): meta-analysis of 654 patients. BMC Neurol. 2016;16:9. doi: 737. Patil A, Shree R, Naheed D, Goyal MK, Mehta S, Ahuja CK, Radotra BD, Lal V. Pearls & oy-sters: paraneoplastic cerebral vasculitis: rare cause of spon- taneous convexity subarachnoid hemorrhage. Neurology. 2018;90:e815 738. Quinones E, Potes LI, Silva N, Lobato-Polo J. Lymphomatoid granulomato- sis of the brain: a case report. Surg Neurol Int. 2016;7(suppl 23):S612 739. Yap S, Naughten E. Homocystinuria due to cystathionine beta-synthase de- ficiency in Ireland: 25 years experience of a newborn screened and treat- ed population with reference to clinical outcome and biochemical control. J Inherit Metab Dis. 1998;21:738 747. doi: 10.1023/a:1005445132327 740. Yap S, Naughten ER, Wilcken B, Wilcken DE, Boers GH. Vascular complications of severe hyperhomocysteinemia in patients with ho- mocystinuria due to cystathionine beta-synthase deficiency: effects of ho- mocysteine-lowering therapy. Semin Thromb Hemost. 2000;26:335 340. 741. El Dib R, Gomaa H, Carvalho RP, Camargo SE, Bazan R, Barretti P, Barreto FC. Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev. 2016;7:CD006663. doi: 742. Germain DP, Elliott PM, Falissard B, Fomin VV, Hilz MJ, Jovanovic A, Kantola I, Linhart A, Mignani R, Namdar M, et al. The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry dis- ease: a systematic literature review by a European panel of experts. Mol Genet Metab Rep. 2019;19:100454. doi: 10.1016/j.ymgmr.2019.100454 743. Rolfs A, B ttcher T, Zschiesche M, Morris P, Winchester B, Bauer P, Walter U, Mix E, L hr M, Harzer K, et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet. 2005;366:1794 744. Wozniak MA, Kittner SJ, Tuhrim S, Cole JW, Stern B, Dobbins M, Grace ME, Nazarenko I, Dobrovolny R, McDade E, et al. Frequency of unrec- ognized Fabry disease among young European-American and African- American men with first ischemic stroke. Stroke. 2010;41:78 81. doi: 745. Bersano A, Kraemer M, Burlina A, Mancuso M, Finsterer J, Sacco S, Salvarani C, Caputi L, Chabriat H, Oberstein SL, et al. Heritable and non-heritable uncommon causes of stroke [published on- line April 21, 2020]. J Neurol. doi: 10.1007/s00415-020-09836-x. 746. Koga Y, Povalko N, Inoue E, Nakamura H, Ishii A, Suzuki Y, Yoneda M, Kanda F, Kubota M, Okada H, et al. Therapeutic regimen of L-arginine for MELAS: 9-year, prospective, multicenter, clinical research. J Neurol. 747. El-Hattab AW, Almannai M, Scaglia F. Arginine and citrulline for the treat- ment of MELAS syndrome. J Inborn Errors Metab Screen. 2017;5:10.1177 748. Haussen DC, Grossberg JA, Bouslama M, Pradilla G, Belagaje S, Bianchi N, Allen JW, Frankel M, Nogueira RG. Carotid web (intimal fibromuscular dysplasia) has high stroke recurrence risk and is amenable to stenting. 749. Haussen DC, Grossberg JA, Koch S, Malik A, Yavagal D, Gory B, Leesch W, Hassan AE, Derelle AL, Richard S, et al. Multicenter experience with stenting for symptomatic carotid web. Interv Neurol. 2018;7:413 418. doi: 750. Zhang AJ, Dhruv P, Choi P, Bakker C, Koffel J, Anderson D, Kim J, Jagadeesan B, Menon BK, Streib C. A systematic literature review of pa- tients with carotid web and acute ischemic stroke. Stroke. 2018;49:2872 751. Coutinho JM, Derkatch S, Potvin AR, Tomlinson G, Casaubon LK, Silver FL, Mandell DM. Carotid artery web and ischemic stroke: a case-control study. CLINICAL STATEMENTS AND GUIDELINES Kleindorfer 752. Gornik HL, Persu A, Adlam D, Aparicio LS, Azizi M, Boulanger M, Bruno RM, de Leeuw P, Fendrikova-Mahlay N, Froehlich J, et al. First international consensus on the diagnosis and management of fibromuscular dysplasia. Vasc Med. 2019;24:164 189. doi: 10.1177/1358863X18821816 753. Weinberg I, Gu X, Giri J, Kim SE, Bacharach MJ, Gray BH, Katzen BT, Matsumoto AH, Chi YW, Rogers KR, et al. Anti-platelet and anti-hyper- tension medication use in patients with fibromuscular dysplasia: results from the United States Registry for Fibromuscular Dysplasia. Vasc Med. 754. Smith LL, Smith DC, Killeen JD, Hasso AN. Operative balloon angioplasty in the treatment of internal carotid artery fibromuscular dysplasia. J Vasc 755. Olin JW, Gornik HL, Bacharach JM, Biller J, Fine LJ, Gray BH, Gray WA, Gupta R, Hamburg NM, Katzen BT, et al; on behalf of the American Heart Association Council on Peripheral Vascular Disease; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; American Heart Association Council on Cardiovascular Disease in the Young; American Heart Association Council on Cardiovascular Radiology and Intervention; American Heart Association Council on Epidemiology and Prevention; American Heart Association Council on Functional Genomics and Translational Biology; American Heart Association Council for High Blood Pressure Research; American Heart Association Council on the Kidney in Cardiovascular Disease; American Heart Association Stroke Council. Fibromuscular dysplasia: state of the science and critical unanswered questions: a scientific statement from the American Heart Association. Circulation. 2014;129:1048 1078. doi: 756. Olin JW, Froehlich J, Gu X, Bacharach JM, Eagle K, Gray BH, Jaff MR, Kim ES, Mace P, Matsumoto AH, et al. The United States Registry for Fibromuscular Dysplasia: results in the first 757. De Groote M, Van der Niepen P, Hemelsoet D, Callewaert B, Vermassen F, Billiouw JM, De Vriese A, Donck J, De Backer T. Fibromuscular dysplasia: results of a multicentre study in Flanders. Vasa. 2017;46:211 218. doi: 758. Schievink WI. Spontaneous dissection of the carotid and verte- bral arteries. N Engl J Med. 2001;344:898 906. doi: 10.1056/ 759. Kadian-Dodov D, Gornik HL, Gu X, Froehlich J, Bacharach JM, Chi YW, Gray BH, Jaff MR, Kim ES, Mace P, et al. Dissection and aneurysm in pa- tients with fibromuscular dysplasia: findings from the U.S. Registry for FMD. J Am Coll Cardiol. 2016;68:176 185. doi: 10.1016/j.jacc.2016.04.044 760. Passero SG, Rossi S. Natural history of vertebrobasilar dolichoectasia. 761. Chen Z, Zhang S, Dai Z, Cheng X, Wu M, Dai Q, Liu X, Xu G. Recurrent risk of ischemic stroke due to vertebrobasilar dolichoectasia. BMC Neurol. 762. Echiverri HC, Rubino FA, Gupta SR, Gujrati M. Fusiform aneurysm of the vertebrobasilar arterial system. Stroke. 1989;20:1741 1747. doi: 763. Wolfe T, Ubogu EE, Fernandes-Filho JA, Zaidat OO. Predictors of clinical outcome and mortality in vertebrobasilar dolichoectasia diagnosed by mag- netic resonance angiography. J Stroke Cerebrovasc Dis. 2008;17:388 764. Wolters FJ, Rinkel GJ, Vergouwen MD. Clinical course and treatment of vertebrobasilar dolichoectasia: a systematic review of the literature. Neurol 765. Gutierrez J, Sacco RL, Wright CB. Dolichoectasia-an evolving arterial dis- ease. Nat Rev Neurol. 2011;7:41 50. doi: 10.1038/nrneurol.2010.181 766. Pico F, Labreuche J, Touboul PJ, Amarenco P; GENIC Investigators. Intracranial arterial dolichoectasia and its relation with atheroscle- rosis and stroke subtype. Neurology. 2003;61:1736 1742. doi: 767. Zhai FF, Yan S, Li ML, Han F, Wang Q, Zhou LX, Ni J, Yao M, Zhang SY, Cui LY, et al. Intracranial arterial dolichoectasia and stenosis: risk factors and relation to cerebral small vessel disease. Stroke. 2018;49:1135 1140. 768. Shapiro M, Becske T, Riina HA, Raz E, Zumofen D, Nelson PK. Non- saccular vertebrobasilar aneurysms and dolichoectasia: a system- atic literature review. J Neurointerv Surg. 2014;6:389 393. doi: 769. Ince B, Petty GW, Brown RD Jr, Chu CP, Sicks JD, Whisnant JP. Dolichoectasia of the intracranial arteries in patients with first ischemic stroke: a population-based study. Neurology. 1998;50:1694 1698. doi: 770. Xu DS, Levitt MR, Kalani MYS, Rangel-Castilla L, Mulholland CB, Abecassis IJ, Morton RP, Nerva JD, Siddiqui AH, Levy EI, et al. Dolichoectatic an- eurysms of the vertebrobasilar system: clinical and radiographic fac- tors that predict poor outcomes. J Neurosurg. 2018;128:560 566. doi: 771. Ubogu EE, Zaidat OO. Vertebrobasilar dolichoectasia diagnosed by mag- netic resonance angiography and risk of stroke and death: a cohort study. J Neurol Neurosurg Psychiatry. 2004;75:22 26. 772. Flemming KD, Wiebers DO, Brown RD Jr, Link MJ, Huston J 3rd, McClelland RL, Christianson TJ. The natural history of radiographically de- fined vertebrobasilar nonsaccular intracranial aneurysms. Cerebrovasc Dis. 773. Bhogal P, P rez MA, Ganslandt O, B zner H, Henkes H, Fischer S. Treatment of posterior circulation non-saccular aneurysms with flow divert- ers: a single-center experience and review of 56 patients. J Neurointerv 774. Siddiqui AH, Abla AA, Kan P, Dumont TM, Jahshan S, Britz GW, Hopkins LN, Levy EI. Panacea or problem: flow diverters in the treatment of symp- tomatic large or giant fusiform vertebrobasilar aneurysms. J Neurosurg. 775. Drake CG, Peerless SJ. Giant fusiform intracranial aneurysms: review of 120 patients treated surgically from 1965 to 1992. J Neurosurg. 776. Anson JA, Lawton MT, Spetzler RF. Characteristics and surgical treatment of dolichoectatic and fusiform aneurysms. J Neurosurg. 1996;84:185 777. Coert BA, Chang SD, Do HM, Marks MP, Steinberg GK. Surgical and endo- vascular management of symptomatic posterior circulation fusiform aneu- 778. Zhang H, Shi M, Tong X. Treatment of symptomatic dolichoectatic verte- brobasilar aneurysms: a single-center experience with 12 patients. World 779. Hart RG, Sharma M, Mundl H, Kasner SE, Bangdiwala SI, Berkowitz SD, Swaminathan B, Lavados P, Wang Y, Wang Y, et al; NAVIGATE ESUS Investigators. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med. 2018;378:2191 2201. doi: 780. Diener HC, Sacco RL, Easton JD, Granger CB, Bernstein RA, Uchiyama S, Kreuzer J, Cronin L, Cotton D, Grauer C, et al; RE-SPECT ESUS Steering Committee and Investigators. Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med. 2019;380:1906 781. Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, Hill MD, Jonasson J, Kasner SE, Ladenvall P, et al; SOCRATES Steering Committee and Investigators. Ticagrelor versus aspirin in acute em- bolic stroke of undetermined source. Stroke. 2017;48:2480 2487. doi: 782. Hart RG, Catanese L, Perera KS, Ntaios G, Connolly SJ. Embolic stroke of undetermined source: a systematic review and clinical update. Stroke. 783. Healey JS, Gladstone DJ, Swaminathan B, Eckstein J, Mundl H, Epstein AE, Haeusler KG, Mikulik R, Kasner SE, Toni D, et al. Recurrent stroke with rivaroxaban compared with aspirin according to predictors of atrial fibrilla- tion: secondary analysis of the NAVIGATE ESUS randomized clinical trial. JAMA Neurol. 2019;76:764 773. doi: 10.1001/jamaneurol.2019.0617 784. Kasner SE, Swaminathan B, Lavados P, Sharma M, Muir K, Veltkamp R, Ameriso SF, Endres M, Lutsep H, Mess SR, et al; NAVIGATE ESUS Investigators. Rivaroxaban or aspirin for patent foramen ovale and em- bolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial. Lancet Neurol. 2018;17:1053 1060. doi: 785. Kamel H, Longstreth WT Jr, Tirschwell DL, Kronmal RA, Broderick JP, Palesch YY, Meinzer C, Dillon C, Ewing I, Spilker JA, et al. The AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke randomized trial: rationale and methods. Int J Stroke. 2019;14:207 786. Geisler T, Poli S, Meisner C, Schreieck J, Zuern CS, N gele T, Brachmann J, Jung W, Gahn G, Schmid E, et al. Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): rationale and study de- sign. Int J Stroke. 2017;12:985 990. doi: 10.1177/1747493016681019 787. Lopes RD, Alings M, Connolly SJ, Beresh H, Granger CB, Mazuecos JB, Boriani G, Nielsen JC, Conen D, Hohnloser SH, et al. Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With CLINICAL STATEMENTS AND GUIDELINES Kleindorfer Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. Am Heart 788. Ratajczak-Tretel B, Lambert AT, Johansen H, Halvorsen B, Bjerkeli V, Russell D, Sandset EC, Ihle-Hansen H, Eriksen E, N ss H, et al. Atrial fibrillation in cryptogenic stroke and transient ischaemic attack: the Nordic Atrial Fibrillation and Stroke (NOR-FIB) study: rationale and design. Eur Stroke J. 2019;4:172 180. doi: 10.1177/2396987319837089 789. De Schryver EL, Algra A, Kappelle LJ, van Gijn J, Koudstaal PJ. Vitamin K antagonists versus antiplatelet therapy after transient isch- aemic attack or minor ischaemic stroke of presumed arterial origin. Cochrane Database Syst Rev. 2012;2012:CD001342. doi: 10.1002/ 790. Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, Kistler JP, Albers GW, Pettigrew LC, Adams HP Jr, et al; Warfarin-Aspirin Recurrent Stroke Study Group. A comparison of warfarin and aspirin for the preven- tion of recurrent ischemic stroke. N Engl J Med. 2001;345:1444 1451. 791. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study, 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1 13. doi: 792. ESPRIT Study Group; Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. 793. Kwok CS, Shoamanesh A, Copley HC, Myint PK, Loke YK, Benavente OR. Efficacy of antiplatelet therapy in secondary prevention following lacunar stroke: pooled analysis of randomized trials. Stroke. 2015;46:1014 1023. 794. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, et al; PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359:1238 1251. doi: 10.1056/NEJMoa0805002 795. Albay CEQ, Leyson FGD, Cheng FC. Dual versus mono antiplatelet therapy for acute non- cardio embolic ischemic stroke or transient ischemic at- tack, an efficacy and safety analysis: updated meta-analysis. BMC Neurol. 796. Naqvi IA, Kamal AK, Rehman H. Multiple versus fewer antiplatelet agents for preventing early recurrence after ischaemic stroke or transient isch- aemic attack. Cochrane Database Syst Rev. 2020;8:CD009716. doi: 797. Johnston SC, Amarenco P, Denison H, Evans SR, Himmelmann A, James S, Knutsson M, Ladenvall P, Molina CA, Wang Y; THALES Investigators. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med. 2020;383:207 217. doi: 10.1056/NEJMoa1916870 798. C t R, Zhang Y, Hart RG, McClure LA, Anderson DC, Talbert RL, Benavente OR. ASA failure: does the combination ASA/clopidogrel confer better long-term vascular protection? Neurology. 2014;82:382 389. doi: 799. Kim JT, Park MS, Choi KH, Cho KH, Kim BJ, Han MK, Park TH, Park SS, Lee KB, Lee BC, et al. Different antiplatelet strategies in patients with new ischemic stroke while taking aspirin. Stroke. 2016;47:128 134. doi: 800. Lee M, Saver JL, Hong KS, Rao NM, Wu YL, Ovbiagele B. Antiplatelet regimen for patients with breakthrough strokes while on aspirin: a sys- tematic review and meta-Analysis. Stroke. 2017;48:2610 2613. doi: 801. Bath PM, Woodhouse LJ, Appleton JP, Beridze M, Christensen H, Dineen RA, Duley L, England TJ, Flaherty K, Havard D, et al; TARDIS Investigators. Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopi- dogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial. 802. Hao Q, Tampi M, O Donnell M, Foroutan F, Siemieniuk RA, Guyatt G. Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: systematic review and meta- analysis. BMJ. 2018;363:k5108. doi: 10.1136/bmj.k5108 803. Rothwell PM, Cook NR, Gaziano JM, Price JF, Belch JFF, Roncaglioni MC, Morimoto T, Mehta Z. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet. 2018;392:387 399. doi: 804. Ding L, Peng B. Efficacy and safety of dual antiplatelet therapy in the el- derly for stroke prevention: a systematic review and meta-analysis. Eur J 805. Kheiri B, Osman M, Abdalla A, Haykal T, Swaid B, Ahmed S, Chahine A, Hassan M, Bachuwa G, Al Qasmi M, et al. Clopidogrel and aspirin after ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized clinical trials. J Thromb Thrombolysis. 806. Patti G, Sticchi A, Bisignani A, Pelliccia F, Pasceri V, Speciale G, Penco M. Meta-regression to identify patients deriving the greatest benefit from dual antiplatelet therapy after stroke or transient ischemic attack without throm- bolytic or thrombectomy treatment. Am J Cardiol. 2019;124:627 635. doi: 807. Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, Jonasson J, Minematsu K, Molina CA, et al; SOCRATES Steering Committee and Investigators. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med. 2016;375:35 43. doi: 808. Amarenco P, Denison H, Evans SR, Himmelmann A, James S, Knutsson M, Ladenvall P, Molina CA, Wang Y, Johnston SC. Ticagrelor added to aspirin in acute ischemic stroke or transient ischemic attack in prevention of dis- abling stroke: a randomized clinical trial. JAMA Neurol. 2020;78:1 9. doi: 809. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, et al; COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377:1319 1330. doi: 810. Joubert J, Reid C, Barton D, Cumming T, McLean A, Joubert L, Barlow J, Ames D, Davis S. Integrated care improves risk-factor modification after stroke: initial results of the Integrated Care for the Reduction of Secondary Stroke model. J Neurol Neurosurg Psychiatry. 2009;80:279 284. doi: 811. Joubert J, Davis SM, Donnan GA, Levi C, Gonzales G, Joubert L, Hankey GJ. ICARUSS: An effective model for risk factor man- agement in stroke survivors. Int J Stroke. 2020;15:438 453. doi: 812. Irewall AL, gren J, Bergstr m L, Laurell K, S derstr m L, Mooe T. Nurse-led, telephone-based, secondary preventive follow-up after stroke or transient ischemic attack improves blood pressure and LDL cho- lesterol: results from the first 12 months of the randomized, controlled NAILED stroke risk factor trial. PLoS One. 2015;10:e0139997. doi: 813. gren J, Irewall AL, S derstr m L, Mooe T. Long-term, telephone-based follow-up after stroke and TIA improves risk factors: 36-month results from the randomized controlled NAILED stroke risk factor trial. BMC Neurol. 814. McAlister FA, Majumdar SR, Padwal RS, Fradette M, Thompson A, Buck B, Dean N, Bakal JA, Tsuyuki R, Grover S, et al. Case manage- ment for blood pressure and lipid level control after minor stroke: PREVENTION randomized controlled trial. CMAJ. 2014;186:577 584. 815. Cheng EM, Cunningham WE, Towfighi A, Sanossian N, Bryg RJ, Anderson TL, Barry F, Douglas SM, Hudson L, Ayala-Rivera M, et al. Efficacy of a chronic care-based intervention on secondary stroke prevention among vulnerable stroke survivors: a randomized con- trolled trial. Circ Cardiovasc Qual Outcomes. 2018;11:e003228. doi: 816. Webster F, Saposnik G, Kapral MK, Fang J, O Callaghan C, Hachinski V. Organized outpatient care: stroke prevention clinic referrals are associated with reduced mortality after transient ischemic attack and ischemic stroke. 817. Ireland SE, Arthur HM, Gunn EA, Oczkowski W. Stroke prevention care delivery: predictors of risk factor management outcomes. Int J Nurs Stud. 818. Ranta A, Dovey S, Weatherall M, O Dea D, Gommans J, Tilyard M. Cluster randomized controlled trial of TIA electronic deci- sion support in primary care. Neurology. 2015;84:1545 1551. doi: 819. Brenner DA, Zweifler RM, Gomez CR, Kissela BM, Levine D, Howard G, Coull B, Howard VJ. Awareness, treatment, and control of vascular risk fac- tors among stroke survivors. J Stroke Cerebrovasc Dis. 2010;19:311 320. 820. Hillen T, Coshall C, Tilling K, Rudd AG, McGovern R, Wolfe CD; South London Stroke Register. Cause of stroke recurrence is multifacto- rial: patterns, risk factors, and outcomes of stroke recurrence in the South London Stroke Register. Stroke. 2003;34:1457 1463. doi: CLINICAL STATEMENTS AND GUIDELINES Kleindorfer 821. Kohok DD, Sico JJ, Baye F, Myers L, Coffing J, Kamalesh M, Bravata DM. Post-stroke hypertension control and receipt of health care services among veterans. J Clin Hypertens (Greenwich). 2018;20:382 387. doi: 822. Mouradian MS, Majumdar SR, Senthilselvan A, Khan K, Shuaib A. How well are hypertension, hyperlipidemia, diabetes, and smoking managed after a stroke or transient ischemic attack? Stroke. 2002;33:1656 1659. doi: 823. Nguyen-Huynh MN, Hills NK, Sidney S, Klingman JG, Johnston SC. Race-ethnicity on blood pressure control after ischemic stroke: a pro- spective cohort study. J Am Soc Hypertens. 2017;11:38 44. doi: 824. Ogilvie IM, Welner SA, Cowell W, Lip GY. Characterization of the proportion of untreated and antiplatelet therapy treated patients with atrial fibrillation. Am J Cardiol. 2011;108:151 161. doi: 10.1016/j.amjcard.2011.02.353 825. White CL, Pergola PE, Szychowski JM, Talbert R, Cervantes-Arriaga A, Clark HD, Del Brutto OH, Godoy IE, Hill MD, Pelegr A, et al; SPS3 Investigators. Blood pressure after recent stroke: baseline findings from the Secondary Prevention of Small Subcortical Strokes trial. Am J 826. Johansson T, Wild C. Telemedicine in acute stroke management: system- atic review. Int J Technol Assess Health Care. 2010;26:149 155. doi: 827. Lyerly MJ, Wu TC, Mullen MT, Albright KC, Wolff C, Boehme AK, Branas CC, Grotta JC, Savitz SI, Carr BG. The effects of telemedicine on racial and ethnic disparities in access to acute stroke care. J Telemed Telecare. 828. Stroke Unit Trialists Collaboration. Organised inpatient (stroke unit) care for stroke. Cochrane Database Syst Rev. 2007:CD000197. doi: 829. Bridgwood B, Lager KE, Mistri AK, Khunti K, Wilson AD, Modi P. Interventions for improving modifiable risk factor control in the secondary prevention of stroke. Cochrane Database Syst Rev. 2018;5:CD009103. 830. Wensing M, Wollersheim H, Grol R. Organizational interventions to im- plement improvements in patient care: a structured review of reviews. Implement Sci. 2006;1:2. doi: 10.1186/1748-5908-1-2 831. Ormseth CH, Sheth KN, Saver JL, Fonarow GC, Schwamm LH. The American Heart Association s Get With The Guidelines (GWTG)-Stroke development and impact on stroke care. Stroke Vasc Neurol. 2017;2:94 832. Ireland S, MacKenzie G, Gould L, Dassinger D, Koper A, LeBlanc K. Nurse case management to improve risk reduction outcomes in a stroke preven- tion clinic. Can J Neurosci Nurs. 2010;32:7 13. 833. Sharrief AZ, Hinojosa E, Cooksey G, Okpala MN, Avritscher EB, Pedroza C, Denny MC, Samuels J, Tyson JE, Savitz SI. Does care in a special- ised stroke prevention clinic improve poststroke blood pressure control: a protocol for a randomised comparative effectiveness study. BMJ Open. 834. Dromerick AW, Gibbons MC, Edwards DF, Farr DE, Giannetti ML, S nchez B, Shara NM, Fokar A, Jayam-Trouth A, Ovbiagele B, et al. Preventing recurrence of thromboembolic events through coordinated treatment in the District of Columbia. Int J Stroke. 2011;6:454 460. doi: 10.1111/j. 835. Toell T, Boehme C, Mayer L, Krebs S, Lang C, Willeit K, Prantl B, Knoflach M, Rumpold G, Schoenherr G, et al. Pragmatic trial of mul- tifaceted intervention (STROKE-CARD care) to reduce cardiovascular risk and improve quality-of-life after ischaemic stroke and transient ischaemic attack -study protocol. BMC Neurol. 2018;18:187. doi: 836. Leistner S, Michelson G, Laumeier I, Ahmadi M, Smyth M, Nieweler G, Doehner W, Sobesky J, Fiebach JB, Marx P, et al. Intensified Secondary Prevention Intending a Reduction of Recurrent Events in TIA and Minor Stroke Patients (INSPiRE-TMS): a protocol for a randomised controlled trial. BMC Neurol. 2013;13:11. doi: 10.1186/1471-2377-13-11 837. Cheng EM, Cunningham WE, Towfighi A, Sanossian N, Bryg RJ, Anderson TL, Guterman JJ, Gross-Schulman SG, Beanes S, Jones AS, et al. Randomized, controlled trial of an intervention to enable stroke survivors throughout the Los Angeles County safety net to stay with the guidelines. Circ Cardiovasc Qual Outcomes. 2011;4:229 234. doi: 838. Duncan PW, Bushnell CD, Jones SB, Psioda MA, Gesell SB, D Agostino RB Jr, Sissine ME, Coleman SW, Johnson AM, Barton-Percival BF, et al; COMPASS Site Investigators and Teams. Randomized pragmatic trial of stroketransitionalcare:theCOMPASSstudy.CircCardiovascQualOutcomes. 839. Wechsler LR, Demaerschalk BM, Schwamm LH, Adeoye OM, Audebert HJ, Fanale CV, Hess DC, Majersik JJ, Nystrom KV, Reeves MJ, et al; on behalf of the American Heart Association Stroke Council; Council on Epidemiology and Prevention; Council on Quality of Care and Outcomes Research. Telemedicine quality and outcomes in stroke: a sci- entific statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2017;48:e3 e25. doi: 840. Lawrence M, Pringle J, Kerr S, Booth J, Govan L, Roberts NJ. Multimodal secondary prevention behavioral interventions for TIA and stroke: a sys- tematic review and meta-analysis. PLoS One. 2015;10:e0120902. doi: 841. Sakakibara BM, Kim AJ, Eng JJ. A systematic review and meta-analysis on self-management for improving risk factor control in stroke patients. Int J Behav Med. 2017;24:42 53. doi: 10.1007/s12529-016-9582-7 842. Barker-Collo S, Krishnamurthi R, Witt E, Feigin V, Jones A, McPherson K, Starkey N, Parag V, Jiang Y, Barber PA, et al. Improving adherence to secondary stroke prevention strategies through motivational inter- viewing: randomized controlled trial. Stroke. 2015;46:3451 3458. doi: 843. Kamal AK, Shaikh Q, Pasha O, Azam I, Islam M, Memon AA, Rehman H, Akram MA, Affan M, Nazir S, et al. A randomized controlled behavioral in- tervention trial to improve medication adherence in adult stroke patients with prescription tailored short messaging service (SMS): SMS4Stroke study. BMC Neurol. 2015;15:212. doi: 10.1186/s12883-015-0471-5 844. Cuccurullo SJ, Fleming TK, Kostis WJ, Greiss C, Gizzi MS, Eckert A, Ray AR, Scarpati R, Cosgrove NM, Beavers T, et al. Impact of a stroke recovery program integrating modified cardiac rehabilitation on all-cause mortality, cardiovascular performance and functional performance. Am J Phys Med 845. Olaiya MT, Cadilhac DA, Kim J, Nelson MR, Srikanth VK, Gerraty RP, Bladin CF, Fitzgerald SM, Phan T, Frayne J, et al. Community-based in- tervention to improve cardiometabolic targets in patients with stroke: a randomized controlled trial. Stroke. 2017;48:2504 2510. doi: 10.1161/ 846. O Donnell MJ, Chin SL, Rangarajan S, Xavier D, Liu L, Zhang H, Rao-Melacini P, Zhang X, Pais P, Agapay S, et al; INTERSTROKE Investigators. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet. 847. Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, Chiuve SE, Cushman M, Delling FN, Deo R, et al; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics 2018 update: a report from the American Heart Association [published correction appears in Circulation. 2018;137:e493]. Circulation. 848. Riegel B, Moser DK, Buck HG, Dickson VV, Dunbar SB, Lee CS, Lennie TA, Lindenfeld J, Mitchell JE, Treat-Jacobson DJ, et al. Self- care for the prevention and management of cardiovascular disease and stroke: a scientific statement for healthcare professionals from the American Heart Association. J Am Heart Assoc. 2017;6:e006997. doi: 849. Lennon O, Blake C, Booth J, Pollock A, Lawrence M. Interventions for behaviour change and self-management in stroke secondary preven- tion: protocol for an overview of reviews. Syst Rev. 2018;7:231. doi: 850. Linden B. NICE public health guidance: individual approaches to behaviour change. Br J Card Nurs. 2014;9:112 113. 851. Lawrence M, Asaba E, Duncan E, Elf M, Eriksson G, Faulkner J, Guidetti S, Johansson B, Kruuse C, Lambrick D, et al. Stroke second- ary prevention, a non-surgical and non-pharmacological consensus definition: results of a Delphi study. BMC Res Notes. 2019;12:823. doi: 852. Oikarinen A, Engblom J, Kyng s H, K ri inen M. A study of the relation- ship between the quality of lifestyle counselling and later adherence to the lifestyle changes based on patients with stroke and TIA. Clin Rehabil. 853. Kronish IM, Diefenbach MA, Edmondson DE, Phillips LA, Fei K, Horowitz CR. Key barriers to medication adherence in survivors of strokes and transient ischemic attacks. J Gen Intern Med. 2013;28:675 682. doi: CLINICAL STATEMENTS AND GUIDELINES Kleindorfer 854. Anderson L, Oldridge N, Thompson DR, Zwisler AD, Rees K, Martin N, Taylor RS. Exercise-based cardiac rehabilitation for coronary heart dis- ease: Cochrane systematic review and meta-analysis. J Am Coll Cardiol. 855. Mackay-Lyons M, Thornton M, Ruggles T, Che M. Non-pharmacological interventions for preventing secondary vascular events after stroke or tran- sient ischemic attack. Cochrane Database Syst Rev. 2013:CD008656. 856. Feldman PH, McDonald MV, Trachtenberg M, Trifilio M, Onorato N, Sridharan S, Silver S, Eimicke J, Teresi J. Reducing hypertension in a poststroke black and hispanic home care population: results of a prag- matic randomized controlled trial. Am J Hypertens. 2020;33:362 370. doi: 857. Boden-Albala B, Goldmann E, Parikh NS, Carman H, Roberts ET, Lord AS, Torrico V, Appleton N, Birkemeier J, Parides M, et al. Efficacy of a discharge educational strategy vs standard discharge care on reduction of vascular risk in patients with stroke and transient ischemic attack: the DESERVE randomized clinical trial. JAMA Neurol. 2019;76:20 27. doi: 858. Kronish IM, Goldfinger JZ, Negron R, Fei K, Tuhrim S, Arniella G, Horowitz CR. Effect of peer education on stroke prevention: the pre- vent recurrence of all inner-city strokes through education random- ized controlled trial. Stroke. 2014;45:3330 3336. doi: 10.1161/ 859. Towfighi A, Cheng EM, Ayala-Rivera M, McCreath H, Sanossian N, Dutta T, Mehta B, Bryg R, Rao N, Song S, et al. Randomized controlled trial of a coordinated care intervention to improve risk factor control af- ter stroke or transient ischemic attack in the safety net: Secondary stroke prevention by Uniting Community and Chronic care model teams Early to End Disparities (SUCCEED). BMC Neurol. 2017;17:24. doi: 860. Churchwell K, Elkind MSV, Benjamin RM, Carson AP, Chang EK, Lawrence W, Mills A, Odom TM, Rodriguez CJ, Rodriguez F, et al; American Heart Association. Call to action: structural racism as a fun- damental driver of health disparities: a presidential advisory from the American Heart Association. Circulation. 2020;142:e454 e468. doi: 861. Lawrence K, Keleher T. Structural Racism. Paper presented at: Race and Public Policy Conference; November 11 13, 2004; Berkeley, CA. 862. Lisabeth LD, Smith MA, Brown DL, Moy LA, Risser JM, Morgenstern LB. Ethnic differences in stroke recurrence. Ann Neurol. 2006;60:469 475. 863. Park JH, Ovbiagele B. Association of black race with recurrent stroke risk. J Neurol Sci. 2016;365:203 206. doi: 10.1016/j.jns.2016.04.012 864. Schwamm LH, Reeves MJ, Pan W, Smith EE, Frankel MR, Olson D, Zhao X, Peterson E, Fonarow GC. Race/ethnicity, quality of care, and outcomes in ischemic stroke. Circulation. 2010;121:1492 1501. doi: 865. Kim O, Ovbiagele B, Valle N, Markovic D, Towfighi A. Race-ethnic disparities in cardiometabolic risk profiles among stroke survivors with undiagnosed diabetes and prediabetes in the United States. J Stroke Cerebrovasc Dis. 2017;26:2727 2733. doi: 10.1016/j. 866. Cruz-Flores S, Rabinstein A, Biller J, Elkind MS, Griffith P, Gorelick PB, Howard G, Leira EC, Morgenstern LB, Ovbiagele B, et al; on behalf of American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Epidemiology and Prevention; Council on Quality of Care and Outcomes Research. Racial-ethnic disparities in stroke care: the American experience: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 867. Reeves MJ, Fonarow GC, Zhao X, Smith EE, Schwamm LH; Get With The Guidelines-Stroke Steering Committee and Investigators. Quality of care in women with ischemic stroke in the GWTG program. Stroke. 868. Harrington RA, Califf RM, Balamurugan A, Brown N, Benjamin RM, Braund WE, Hipp J, Konig M, Sanchez E, Joynt Maddox KE. Call to action: ru- ral health: a presidential advisory from the American Heart Association and American Stroke Association. Circulation. 2020;141:e615 e644. doi: 869. Caceres BA, Streed CG Jr, Corliss HL, Lloyd-Jones DM, Matthews PA, Mukherjee M, Poteat T, Rosendale N, Ross LM; on behalf of the American Heart Association Council on Cardiovascular and Stroke Nursing; Council on Hypertension; Council on Lifestyle and Cardiometabolic Health; Council on Peripheral Vascular Disease; and Stroke Council. Assessing and ad- dressing cardiovascular health in LGBTQ adults: a scientific statement from the American Heart Association. Circulation. 2020;142:e321 e332. 870. Addo J, Ayerbe L, Mohan KM, Crichton S, Sheldenkar A, Chen R, Wolfe CD, McKevitt C. Socioeconomic status and stroke: an updated review. Stroke. 871. Marshall IJ, Wang Y, Crichton S, McKevitt C, Rudd AG, Wolfe CD. The ef- fects of socioeconomic status on stroke risk and outcomes. Lancet Neurol. 872. Avan A, Digaleh H, Di Napoli M, Stranges S, Behrouz R, Shojaeianbabaei G, Amiri A, Tabrizi R, Mokhber N, Spence JD, et al. Socioeconomic status and stroke incidence, prevalence, mortality, and worldwide burden: an eco- logical analysis from the Global Burden of Disease Study 2017. BMC Med. 873. Schultz WM, Kelli HM, Lisko JC, Varghese T, Shen J, Sandesara P, Quyyumi AA, Taylor HA, Gulati M, Harold JG, et al. Socioeconomic status and cardiovascular outcomes: challenges and interventions. Circulation. 874. Trivedi AN, Nsa W, Hausmann LR, Lee JS, Ma A, Bratzler DW, Mor MK, Baus K, Larbi F, Fine MJ. Quality and equity of care in U.S. hospitals. N Engl J Med. 2014;371:2298 2308. doi: 10.1056/NEJMsa1405003 875. Beauchamp A, Peeters A, Tonkin A, Turrell G. Best practice for pre- vention and treatment of cardiovascular disease through an equity lens: a review. Eur J Cardiovasc Prev Rehabil. 2010;17:599 606. doi: 876. Malambo P, Kengne AP, De Villiers A, Lambert EV, Puoane T. Built en- vironment, selected risk factors and major cardiovascular disease outcomes: a systematic review. PLoS One. 2016;11:e0166846. doi: 877. Billioux AK, Verlander K, Anthony S, Alley D. 2017. Standardized screening for health-related social needs in clinical settings: the accountable health communities screening tool. NAM Perspectives. Discussion Paper, National Academy of Medicine, Washington, DC. Accessed December 1, 2019. 878. Morgenstern LB, Dohodwala N, Frontera-Roura W, Nath A, Ovbiagele B, Ramirez A, Trevathan E, Vickrey B. Report from the Strategic Planning Advisory Panel on Health Disparities: report of the NINDS Advisory Panel on Health Disparities Research. 2010. Accessed December 1, disparities_rpt.pdf 879. Brega A, Barnard J, Mabachi N, Weiss B, DeWalt D, Brach C, Cifuentes M, Albright K, West D. AHRQ Health Literacy Universal Precautions Toolkit. Accessed December 1, 2019. https://www.ahrq.gov/sites/default/files/ wysiwyg/professionals/quality-patient-safety/quality-resources/tools/ 880. Magnani JW, Mujahid MS, Aronow HD, Cen CW, Dickson VV, Havranek E, Morgenstern LB, Paasche-Orlow MK, Pollak A, Willey JZ; on behalf of the American Heart Association Council on Epidemiology and Prevention; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research; and Stroke Council. Health literacy and cardiovascular disease: fundamental relevance to primary and second- ary prevention: a scientific statement from the American Heart Association.